MIF mRNA Expression and Soluble Levels in Acute Coronary Syndrome

Acute coronary syndrome (ACS) describes any condition characterized by myocardial ischaemia and reduction in blood flow. The physiopathological process of ACS is the atherosclerosis where MIF operates as a major regulator of inflammation. The aim of this study was to assess the mRNA expression of MI...

Full description

Saved in:
Bibliographic Details
Published in:Cardiology research and practice 2018-01, Vol.2018 (2018), p.1-6
Main Authors: Padilla-Gutiérrez, Jorge Ramón, Sandoval-Pinto, Elena, Flores-Salinas, Hector Enrique, Valdez-Haro, Angélica, García-González, Ilian Janet, Muñoz-Valle, Jose F., Valle, Yeminia, Valdés-Alvarado, Emmanuel, Pérez-Ibarra, Jorge Manuel
Format: Article
Language:English
Subjects:
Acute coronary syndromes
Angina pectoris
Atherosclerosis
Biomarkers
Blood pressure
Cardiovascular disease
Cell adhesion & migration
Coronary heart disease
Cytokines
Diabetes
Endothelium
Enzyme-linked immunosorbent assay
Enzymes
Ethylenediaminetetraacetic acid
Gene expression
Genes
Health risk assessment
Heart attacks
Hypertension
Hypoxia
Inflammation
Ischemia
Kinases
Messenger RNA
Obesity
Risk factors
Software
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute coronary syndrome (ACS) describes any condition characterized by myocardial ischaemia and reduction in blood flow. The physiopathological process of ACS is the atherosclerosis where MIF operates as a major regulator of inflammation. The aim of this study was to assess the mRNA expression of MIF gene and its serum levels in the clinical manifestations of ACS and unrelated individuals age- and sex-matched with patients as the control group (CG). All samples were run using the conditions indicated in TaqMan Gene Expression Assay protocol. Determination of MIF serum levels were performed by enzyme-linked immunosorbent assay and MIF ELISA Kit. ST-segment elevation myocardial infraction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) showed 0.8 and 0.88, respectively, less expression of MIF mRNA with regard to CG. UA and STEMI presented more expression than NSTEMI 5.23 and 0.68, respectively. Otherwise, ACS patients showed significant higher MIF serum levels (p=0.02) compared with CG. Furthermore, the highest soluble levels of MIF were presented by STEMI (11.21 ng/dL), followed by UA (10.34 ng/dL) and finally NSTEMI patients (8.75 ng/dL); however, the differences were not significant. These novel observations further establish the process of MIF release after cardiovascular events and could support the idea of MIF as a new cardiac biomarker in ACS.
ISSN:2090-8016
2090-0597
2090-0597
DOI:10.1155/2018/9635652